New drug combo aims to spare bladders in cancer patients
NCT ID NCT07475806
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a combination of enfortumab vedotin and pembrolizumab can help people with muscle-invasive bladder cancer avoid bladder removal. About 240 adults who are candidates for surgery will receive the drugs intravenously. The main goals are to see how many achieve a complete response and keep their bladder for at least 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enfortumab vedotin and pembrolizumab
What this could lead to
If successful, this could offer a way to treat muscle-invasive bladder cancer without removing the bladder, preserving quality of life.
What could go wrong
This is a mid-stage trial with no control group, so results are uncertain. The treatment may not work for everyone, and side effects like nerve damage or uncontrolled diabetes could occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Accellacare of Duly
RECRUITINGLisle, Illinois, 60532, United States
-
Arkansas Urology Associates
RECRUITINGLittle Rock, Arkansas, 72211, United States
-
Carolina Urologic Research Center
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
-
Centers for Advanced Urology, LLP
RECRUITINGBala-Cynwyd, Pennsylvania, 19004, United States
-
NYU Langone Urology Associates
RECRUITINGNew York, New York, 10017, United States
-
Sidney Kimmel Comprehensive Cancer - Asplundh Cancer Pavilion
RECRUITINGWillow Grove, Pennsylvania, 19090, United States
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
University of Illinois College of Medicine - UIC Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
-
Urology San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States